Combined therapy with L-carnitine and erythropoietin of anemia in chronic kidney failure patients undergoing hemodialysis;Skojarzone leczenie niedokrwistości L-karnityna̧ i erytropoetyna̧ u chorych na przewlekła̧ niewydolnoś ć nerek poddanych hemodializoterapii

Polskie Archiwum Medycyny Wewnetrznej

Volumn 117, Issue 1-2, 2007, Pages 14-19

  Wanic Kossowska, Maria ^a   Kaźmierski, Marek ^b   Pawliczak, Elzbieta ^a   Kobelski, Mikołaj ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Oddzia Chorób Wewn trznych   (Poland)

Author keywords

Anemia; Chronic renal failure; L carnitine and erythropoietin treatment

Indexed keywords

CARNITINE; ERYTHROPOIETIN; PARATHYROID HORMONE;

ADULT; ANEMIA; ARTICLE; CHRONIC KIDNEY FAILURE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REDUCTION; HEMATOLOGICAL PARAMETERS; HEMODIALYSIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 34249935059     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.63     Document Type: Article

References (18)

1. Azzadin A, Wollny T, Pawlak R, et al. L-carnitine effects on anemia in uremic rats treated with erythropoietin. Nephron 1999; 83: 370-371.
2. Kletzmayer J, Mayer G, Legenstein E, et al. Anemia and carnitine supplementation in hemodialyzed patients. Kidney Int Suppl. 1999; 69: s93-s106.
3. Labonia WD. L-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin. Am J Kidney Dis. 1995; 26: 757-764.
4. Cheng JT, Kahn T, Kaji DM. Mechanism of alternation of sodium potassium pump of erythrocytes from patients with chronic renal failure. J Clin Invest. 1984; 74: 1811-1820.
5. Arduini A, Mancinelli G, Rudatti GL, et al. Role of carnitine palmityltransferase as integral components of the pathway for membrane phospholipid fatty acid turnover in intact human erythrocytes. J Biol Chem. 1992; 267: 12673-12681.
6. Witko-Sarsat V, Friedlander M., Capeillere-Blandin C, et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996; 49: 1304-1313.
7. Reznick AZ, Kagan VE, Ramsey R, et al. Antiradical effects in L-propionyl carnitine protection of the heart against ischemia-reperflision injury: the possible role of iron chelation. Arch Biochem Biophys. 1992; 296: 394-401.
8. Rosner B. Fundamental of biostatistic. Harvard University, 1986.
9. Labonia WD, Morelli OH, Gimenez ML, et al. Effects of L-carnitine on sodium transport in erythrocytes from dialyzed uremic patients. Kidney Int. 1987; 32: 754-759.
10. Boran M, Dalva L, Gonenc F, Cetin S. Response to recombinant human erythropoietin (r-HuEPO) and L-carnitine combination in patients with anemia of end-stage renal disease. Nephron 1996; 73: 314-315.
11. Kitamura Y, Satoh K, Satoh T, et al. Effect of L-carnitine on erythroid colony formation in mouse bone marrow cells. Nephrol Dial Transplant. 2005; 20: 981-984.
12. Trovato GM, Ginardi V, Di Marco V, et al. Long-term L-carnitine treatment of chronic anemia of patients with end stage renal failure. Curr Ther Res. 1982; 31: 1042-1049.
13. Vlassoupoulos DA, Hadjiyannakos DK, Anogiatis AG, et al. Carnitine action on red blood cells osmotic resistance in hemodialysis patients. J Nephrol. 2002; 15: 68-73.
14. Matsumoto Y, Amano I, Hirose S, et al. Effects of L-carnitine supplementation on renal anemia in poor responders to erythropoietin. Blood Purif. 2001; 19: 24-32.
15. Sotirakopoulos A, Athanasiou G, Tsitsios T, Mavromatidis K. The influence of L-carnitine supplementation on hematocrit and hemoglobin levels in patients with end stage renal failure on CAPD. Ren Fail. 2002; 24: 505-510.
16. Kooistra MP, Struyvenberg A, van Es A. The response in recombinant human erythropoietin in patients with the anemia of end-stage renal disease is correlated with serum carnitine levels. Nephron 1991; 57: 127-128.
17. Golper TA, Goral S, Becker BN, Longman CB. L-carnitine treatment of anemia. Am J Kidney Dis. 2003; 41 (suppl. 4): s27-s28.
18. Steinman TI, Nissenson AR, Glassock RJ, et al. L-carnitine use in dialysis patients is national coverage for supplementation justified? What were CMS regulators thinking-or were they? Nephrol News Issues 2003; 17: 28-30.